Cita APA

Herbst, R., Garon, E., Kim, D., Cho, B., Gervais, R., Perez-Gracia, J., . . . Baas, P. (2021). Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.

Citación estilo Chicago

Herbst, RS, et al. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. 2021.

Cita MLA

Herbst, RS, et al. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. 2021.